Pacira Pharm Inc (PCRX) 38.79 $PCRX Technical Analysis

New Post Public Reply Private Reply Replies (0) Message Board

Jun 24, 2016 at 1:15 PM

Pacira Pharm Inc (PCRX) 38.79 $PCRX

Technical Analysis on Drugs - Generic Equities -- Akorn, Ironwood Pharma, Catalyst Pharma, and Pacira Pharma
PR Newswire - Fri Jun 10, 7:00AM CDT
On Thursday, June 09, 2016, the NASDAQ Composite ended the trading session at 4,958.62, down 0.32%; the Dow Jones Industrial Average edged 0.11% lower to finish at 17,985.19; and the S&P 500 closed at 2,115.48, down 0.17%. ActiveWallSt.com has initiated coverage on the following equities: Akorn Inc. (NASDAQ: AKRX), Ironwood Pharmaceuticals Inc. (NASDAQ: IRWD), Catalyst Pharmaceuticals Inc. (NASDAQ: CPRX), and Pacira Pharmaceuticals Inc. (NASDAQ: PCRX). Learn more about these stocks by accessing their free trade alerts at:
IRWD: 12.30 (-0.65), CPRX: 0.80 (-0.08), AKRX: 27.94 (-1.16), PCRX: 38.79 (-1.20)

Pacira Pharmaceuticals, Inc. to Present at the Jefferies 2016 Healthcare Conference
GlobeNewswire - Tue May 31, 6:30AM CDT
Pacira Pharmaceuticals, Inc. (NASDAQ

CRX) today announced that Dave Stack, Chief Executive Officer and Chairman of Pacira Pharmaceuticals, is scheduled to present at the Jefferies 2016 Healthcare Conference at 9 a.m. ET on Tuesday, June 7, 2016, in New York. Mr. Stack is expected to present an overview of the company.
PCRX: 38.79 (-1.20)

Pacira Pharmaceuticals, Inc. to Present at the Bank of America Merrill Lynch 2016 Health Care Conference
GlobeNewswire - Tue May 03, 6:30AM CDT
Pacira Pharmaceuticals, Inc. (NASDAQ

CRX) today announced that Jim Scibetta, President of Pacira Pharmaceuticals, is scheduled to present at the Bank of America Merrill Lynch 2016 Health Care Conference at 8:40 a.m. PT (11:40 a.m. ET) on Tuesday, May 10, 2016, in Las Vegas. Mr. Scibetta is expected to present an overview of the company.
PCRX: 38.79 (-1.20)

Pacira Pharmaceuticals Inc.'s Double-Digit Drop Explained
Sean Williams, The Motley Fool - Motley Fool - Mon May 02, 3:02PM CDT
Image source: NIH Image Gallery via Flickr. What: Shares of Pacira Pharmaceuticals , a specialty pharmaceutical company primarily focused on the development of medicines to help in the acute hospital care setting, dipped by as much as 10%...
PCRX: 38.79 (-1.20)

Pacira reports 1Q loss
Automated Insights - Mon May 02, 6:40AM CDT
PARSIPPANY, N.J. (AP) _ Pacira Pharmaceuticals Inc. (PCRX) on Monday reported a first-quarter loss of $3.9 million, after reporting a profit in the same period a year earlier.
PCRX: 38.79 (-1.20)

Pacira Pharmaceuticals, Inc. Reports First Quarter 2016 Financial Results
GlobeNewswire - Mon May 02, 6:34AM CDT
-- Total Net Revenues Up 12 Percent Year-Over-Year --
PCRX: 38.79 (-1.20)

Pacira Pharmaceuticals Appoints Charles A. Reinhart, III, as Chief Financial Officer
GlobeNewswire - Tue Apr 19, 7:00AM CDT
Pacira Pharmaceuticals, Inc. (NASDAQ

CRX) today announced the appointment of Charles A. Reinhart, III, to the position of Chief Financial Officer. Mr. Reinhart will be responsible for overseeing all financial and capital market activities at Pacira, including accounting, financial reporting, financial planning and analysis and investor relations. In this position, he will succeed former Chief Financial Officer Jim Scibetta, who is currently President, and will report to Dave Stack, Chief Executive Officer and Chairman. Mr. Reinhart will start in this new role effective Tuesday, May 3, 2016.
PCRX: 38.79 (-1.20)

Pacira Pharmaceuticals (PCRX) is Overbought: Is A Drop Coming?
Zacks Equity Research - Zacks Investment Research - Fri Apr 15, 7:48AM CDT
Pacira Pharmaceuticals, Inc. (PCRX) has moved higher as of late, but there could definitely be trouble on the horizon for this company
PCRX: 38.79 (-1.20)

Pacira Pharmaceuticals Announces Timing for First Quarter 2016 Financial Results Webcast and Conference Call
GlobeNewswire - Thu Apr 14, 6:30AM CDT
Pacira Pharmaceuticals, Inc. (NASDAQ

CRX) today announced that financial results for the company's first quarter ended March 31, 2016 will be released before the market opens on Monday, May 2, 2016. The Pacira management team will host a conference call to discuss the company's financial results and recent and upcoming developments on Monday, May 2, 2016, at 9 a.m. ET. The call can be accessed by dialing 1-877-845-0779 (domestic) or 1-720-545-0035 (international) ten minutes prior to the start of the call and providing the Conference ID 54803652.
PCRX: 38.79 (-1.20)

Pacira Pharmaceuticals Appoints Robert Weiland as Chief Commercial Officer
GlobeNewswire - Tue Apr 05, 6:30AM CDT
Pacira Pharmaceuticals, Inc. (NASDAQ

CRX) today announced the appointment of Robert Weiland to the position of Chief Commercial Officer. Mr. Weiland will be responsible for oversight of the commercial activities for EXPAREL (bupivacaine liposome injectable suspension), which include marketing, sales, national accounts, training and commercial operations and analytics. Mr. Weiland will report to Jim Scibetta, President and Chief Financial Officer.
PCRX: 38.79 (-1.20)

Pacira (PCRX): Moving Average Crossover Alert
Zacks Equity Research - Zacks Investment Research - Tue Mar 15, 9:05AM CDT
Pacira Pharmaceuticals, Inc. (PCRX) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front
PCRX: 38.79 (-1.20)

PixarBio's NeuroRelease(TM) A Revolutionary Non Addictive Pain Treatment Draws Pain Industry Star Sales Executive David Kaplan as Global VP of Sales & Marketing
BusinessWire - Wed Mar 09, 5:00AM CST
PixarBio Corporation inventors of NeuroRelease, a 14 day non-addictive post-surgical pain treatment with expected FDA approval in 2018, announced today the appointment of David Kaplan as Vice President of Global Sales and Marketing.
PCRX: 38.79 (-1.20)

Pacira Pharmaceuticals, Inc. to Present at the Barclays Global Healthcare Conference
GlobeNewswire - Tue Mar 08, 6:30AM CST
Pacira Pharmaceuticals, Inc. (NASDAQ

CRX) today announced that Dave Stack, chief executive officer and chairman of Pacira Pharmaceuticals, is scheduled to present at the Barclays Global Healthcare Conference at 9 a.m. ET on Tuesday, March 15, 2016, in Miami. Mr. Stack is expected to present an overview of the company.
PCRX: 38.79 (-1.20)

CTI BioPharma's Myelofibrosis Drug on Full Clinical Hold
Zacks Equity Research - Zacks Investment Research - Wed Feb 10, 3:04PM CST
CTI BioPharma Corp. (CTIC) announced that the FDA has placed the company's Investigational New Drug (IND) application for pacritinib on a full clinical hold.
GILD: 80.48 (-2.89), MYL: 43.31 (-2.85), CTIC: 0.36 (-0.04), PCRX: 38.79 (-1.20)

Catalyst (CPRX) Initiates Study on Firdapse for MuSK-MG
Zacks Equity Research - Zacks Investment Research - Tue Feb 09, 3:25PM CST
Catalyst Pharmaceuticals, Inc. (CPRX) announced the initiation of a well-controlled study evaluating the efficacy, safety and tolerability of Firdapse for the treatment of MuSK-MG.
EARS: 3.83 (-0.17), CPRX: 0.80 (-0.08), CORT: 5.19 (-0.28), PCRX: 38.79 (-1.20)

Shire's NDA Resubmission for Lifitegrast Accepted by FDA
Zacks Equity Research - Zacks Investment Research - Fri Feb 05, 3:15PM CST
Shire plc (SHPG) announced that the FDA has acknowledged the receipt of the company's New Drug Application (NDA) for its pipeline candidate, lifitegrast.
AGN: 226.98 (-6.53), SHPG: 166.84 (-13.45), CORT: 5.19 (-0.28), PCRX: 38.79 (-1.20)

Conatus Up on Fast Track Status for Emricasan in the U.S.
Zacks Equity Research - Zacks Investment Research - Thu Feb 04, 1:40PM CST
Shares of Conatus Pharmaceuticals Inc. (CNAT) soared 22.5% after the company announced that the FDA has granted Fast Track designation to the company's lead pipeline candidate, emricasan,
CNAT: 2.00 (-0.13), CORT: 5.19 (-0.28), PCRX: 38.79 (-1.20), BIOD: 0.31 (unch)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Gong, Agentforce, Avoma Crowned 2026 CI Champions

Diving Deep into Conversation Intelligence There's a lot to unpack when three software titans hog the spotlight, and that's exactly what's happening in the world of conversation intelligence this year. It's like we've hit the jackpot with Gong, Agentforce Sales, and Avoma carving out their turf as the 2026 Champions, according to the venerable Info-Tech Research Group....

Vitamin Angels Drives Global Nutrition Advancements

Navigating the Waters of Global Nutrition Bet you never thought a vitamin program could spearhead the front lines of healthcare, huh? Vitamin Angels are grinding away under the radar, shifting the landscape for maternal and child nutrition. At the heart of it all is their vision to make UNIMMAP multiple micronutrient supplementation (MMS) a staple in the global playbook....

U. of Phoenix and LACCD Launch 3+1 Degree Pathway

Opening the Floodgates for Ambitious Community College Students When it comes to climbing the educational ladder, not everyone starts at the same rung. That's a fact we've all come to terms with in one way or another. Enter the University of Phoenix and the Los Angeles Community College District with a solution to expand educational access. The 3+1 Program: A Cost-Saving...

OCI N.V. Secures a Win in Court; EGM Proceeds as Planned

OCI Dodges a Bullet in Amsterdam Court Stepping into the courtroom drama, OCI N.V. just took home a win as the Amsterdam Court of Appeal's Enterprise Chamber gave them a clean bill of health, kicking out the inquiry request from VEB and a bunch of other shareholders. The judges weren't convinced there was anything fishy going on, so they tossed the inquiry petition and...

C3EL Expands Federal Footprint with Strategic Contracts

Pushing Boundaries in Federal Contracts What a ride C3EL's had in Government Fiscal Year 2026! Let me tell you, they’ve bagged a bunch of contracts that’d make any company’s mouth water. Kicking things off, they snagged a prime cybersecurity contract from the U.S. Air Force. Considering our current cybersecurity landscape, that's like striking gold. But they...

Wally Disrupts Dental Industry with $25M Funding

A New Breath of Fresh Air for Dental Care Dental visits—a tedious, costly affair we've all dreaded. So, when Wally rolls out an overhaul in this stale landscape, it's worth taking notice. With $25 million in their pockets from Series A funding led by Maveron, Wally's swaggering in with a plan to flip the script on dental care across the nation. Redefining the Dental...

Duke Energy's Cost-Protection Plan Shields Ratepayers

Shielding Customers From Data Center Costs Let's get right into the thick of it: Duke Energy's latest move is a strategic one, shrouded in industry terms but with a real impact on regular folks' wallets. The company's agreement with heavyweights like Amazon, Google, and Meta aims to protect existing customers in North Carolina from getting hit with the costs of powering...

HelloNation Brings 'Edvertising' to NC REALTORS® Event

HelloNation's Bold Step into Real Estate Networking October 8th to the 11th is shaping up to be a pivotal few days in Wilmington, North Carolina. Here’s the scoop: HelloNation, known for its innovative 'edvertising' model, is joining the bustling crowd at the 2026 NC REALTORS® Convention. This isn’t just any get-together—it's the grandest annual jamboree for real...

Merit Expands in New York with Bold Acquisition Move

Merit Financial's Growth Trajectory Takes a Leap You watch the movers and shakers in this game long enough, and you start to see patterns. Merit Financial Advisors is one of those juggernauts you'd better keep an eye on. These folks just scooped up Moldenhauer & Associates—a firm that's been a staple in Orchard Park, New York—for a cool $1.1 billion worth of client...

EMCO's New Automated Facility Could Shake Industry

A Novel Leap in Production Capacity EMCO Industries just put a solid foot on the accelerator with their brand-new, shiny, fully automated plant over in Claremore, Oklahoma. If you're glancing at heavy-duty trailer springs, you can't ignore the fact that this is a multimillion-dollar investment. Heck, this monstrous 30,000-square-foot facility more than doubles what EMCO...